vs

Side-by-side financial comparison of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) and OptimizeRx Corp (OPRX). Click either name above to swap in a different company.

OptimizeRx Corp is the larger business by last-quarter revenue ($32.2M vs $22.6M, roughly 1.4× KESTRA MEDICAL TECHNOLOGIES, LTD.). OptimizeRx Corp runs the higher net margin — 15.6% vs -145.3%, a 160.9% gap on every dollar of revenue. OptimizeRx Corp produced more free cash flow last quarter ($7.1M vs $-25.6M).

Kestra Medical Technologies, Ltd. is a medical device firm that develops, manufactures and commercializes innovative minimally invasive therapeutic solutions, mainly for interventional cardiology and structural heart disease treatment. It operates across North America, Europe and key Asia-Pacific markets, serving global healthcare providers and patients.

OptimizeRx Corp is a U.S.-headquartered digital health technology company that delivers patient engagement, medication affordability and clinical communication solutions to life sciences enterprises, healthcare providers and pharmacy partners. Its core offerings include digital medication savings tools, patient support programs, and therapeutic area-specific resources to boost medication access and treatment adherence.

KMTS vs OPRX — Head-to-Head

Bigger by revenue
OPRX
OPRX
1.4× larger
OPRX
$32.2M
$22.6M
KMTS
Higher net margin
OPRX
OPRX
160.9% more per $
OPRX
15.6%
-145.3%
KMTS
More free cash flow
OPRX
OPRX
$32.7M more FCF
OPRX
$7.1M
$-25.6M
KMTS

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
KMTS
KMTS
OPRX
OPRX
Revenue
$22.6M
$32.2M
Net Profit
$-32.8M
$5.0M
Gross Margin
50.6%
74.8%
Operating Margin
-140.7%
26.6%
Net Margin
-145.3%
15.6%
Revenue YoY
-0.2%
Net Profit YoY
6535.9%
EPS (diluted)
$-0.64
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KMTS
KMTS
OPRX
OPRX
Q4 25
$22.6M
$32.2M
Q3 25
$19.4M
$26.1M
Q2 25
$29.2M
Q1 25
$21.9M
Q4 24
$32.3M
Q3 24
$21.3M
Q2 24
$18.8M
Q1 24
$19.7M
Net Profit
KMTS
KMTS
OPRX
OPRX
Q4 25
$-32.8M
$5.0M
Q3 25
$-25.8M
$779.0K
Q2 25
$1.5M
Q1 25
$-2.2M
Q4 24
$-78.0K
Q3 24
$-9.1M
Q2 24
$-4.0M
Q1 24
$-6.9M
Gross Margin
KMTS
KMTS
OPRX
OPRX
Q4 25
50.6%
74.8%
Q3 25
45.7%
67.2%
Q2 25
63.8%
Q1 25
60.9%
Q4 24
68.1%
Q3 24
63.1%
Q2 24
62.2%
Q1 24
62.0%
Operating Margin
KMTS
KMTS
OPRX
OPRX
Q4 25
-140.7%
26.6%
Q3 25
-149.1%
7.9%
Q2 25
10.9%
Q1 25
-9.6%
Q4 24
11.2%
Q3 24
-40.2%
Q2 24
-19.9%
Q1 24
-25.5%
Net Margin
KMTS
KMTS
OPRX
OPRX
Q4 25
-145.3%
15.6%
Q3 25
-133.3%
3.0%
Q2 25
5.2%
Q1 25
-10.0%
Q4 24
-0.2%
Q3 24
-42.8%
Q2 24
-21.3%
Q1 24
-35.0%
EPS (diluted)
KMTS
KMTS
OPRX
OPRX
Q4 25
$-0.64
$0.27
Q3 25
$-0.50
$0.04
Q2 25
$0.08
Q1 25
$-0.12
Q4 24
$0.00
Q3 24
$-0.50
Q2 24
$-0.22
Q1 24
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KMTS
KMTS
OPRX
OPRX
Cash + ST InvestmentsLiquidity on hand
$175.4M
$23.4M
Total DebtLower is stronger
$26.3M
Stockholders' EquityBook value
$164.1M
$128.3M
Total Assets
$246.7M
$176.9M
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KMTS
KMTS
OPRX
OPRX
Q4 25
$175.4M
$23.4M
Q3 25
$201.2M
$19.5M
Q2 25
$16.6M
Q1 25
$16.6M
Q4 24
$13.4M
Q3 24
$16.1M
Q2 24
Q1 24
Total Debt
KMTS
KMTS
OPRX
OPRX
Q4 25
$26.3M
Q3 25
$28.8M
Q2 25
$29.3M
Q1 25
$33.8M
Q4 24
$34.3M
Q3 24
$36.8M
Q2 24
$37.3M
Q1 24
$37.8M
Stockholders' Equity
KMTS
KMTS
OPRX
OPRX
Q4 25
$164.1M
$128.3M
Q3 25
$184.2M
$122.3M
Q2 25
$119.3M
Q1 25
$116.3M
Q4 24
$117.0M
Q3 24
$114.5M
Q2 24
$121.0M
Q1 24
$122.5M
Total Assets
KMTS
KMTS
OPRX
OPRX
Q4 25
$246.7M
$176.9M
Q3 25
$266.3M
$170.3M
Q2 25
$169.3M
Q1 25
$167.8M
Q4 24
$171.2M
Q3 24
$165.2M
Q2 24
$172.9M
Q1 24
$176.4M
Debt / Equity
KMTS
KMTS
OPRX
OPRX
Q4 25
0.20×
Q3 25
0.24×
Q2 25
0.25×
Q1 25
0.29×
Q4 24
0.29×
Q3 24
0.32×
Q2 24
0.31×
Q1 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KMTS
KMTS
OPRX
OPRX
Operating Cash FlowLast quarter
$-18.3M
$7.1M
Free Cash FlowOCF − Capex
$-25.6M
$7.1M
FCF MarginFCF / Revenue
-113.5%
22.0%
Capex IntensityCapex / Revenue
32.2%
0.0%
Cash ConversionOCF / Net Profit
1.41×
TTM Free Cash FlowTrailing 4 quarters
$18.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KMTS
KMTS
OPRX
OPRX
Q4 25
$-18.3M
$7.1M
Q3 25
$-26.3M
$3.2M
Q2 25
$4.6M
Q1 25
$3.9M
Q4 24
$198.0K
Q3 24
$1.8M
Q2 24
$782.0K
Q1 24
$2.1M
Free Cash Flow
KMTS
KMTS
OPRX
OPRX
Q4 25
$-25.6M
$7.1M
Q3 25
$-34.4M
$3.2M
Q2 25
$4.6M
Q1 25
$3.8M
Q4 24
$181.0K
Q3 24
$1.8M
Q2 24
$737.0K
Q1 24
$2.1M
FCF Margin
KMTS
KMTS
OPRX
OPRX
Q4 25
-113.5%
22.0%
Q3 25
-177.8%
12.2%
Q2 25
15.6%
Q1 25
17.5%
Q4 24
0.6%
Q3 24
8.3%
Q2 24
3.9%
Q1 24
10.6%
Capex Intensity
KMTS
KMTS
OPRX
OPRX
Q4 25
32.2%
0.0%
Q3 25
42.2%
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.1%
Q2 24
0.2%
Q1 24
0.2%
Cash Conversion
KMTS
KMTS
OPRX
OPRX
Q4 25
1.41×
Q3 25
4.11×
Q2 25
2.98×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons